Chrystal Jensen Sells 113,008 Shares of Cerus (NASDAQ:CERS) Stock

Cerus Corporation (NASDAQ:CERS) insider Chrystal Jensen sold 113,008 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $1.66, for a total value of $187,593.28. Following the transaction, the insider owned 946,131 shares of the company’s stock, valued at $1,570,577.46. This represents a 10.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Chrystal Jensen also recently made the following trade(s):

• On Friday, March 6th, Chrystal Jensen sold 30,845 shares of Cerus stock. The shares were sold at an average price of $2.01, for a total transaction of $61,998.45.

Cerus Stock Performance

Shares of CERS opened at $1.80 on Wednesday. The stock has a market capitalization of $345.91 million, a PE ratio of -22.50 and a beta of 1.51. The company’s fifty day moving average is $2.28 and its 200 day moving average is $1.88. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.17 and a current ratio of 1.73. Cerus Corporation has a fifty-two week low of $1.12 and a fifty-two week high of $2.96.

Cerus (NASDAQ:CERS) last released its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. The business had revenue of $64.58 million during the quarter, compared to analyst estimates of $59.31 million. Sell-side analysts expect that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.

Key Stories Impacting Cerus

Here are the key news stories impacting Cerus this week:

• Positive Sentiment: Cerus named COO Vivek Jayaraman as President & Chief Executive Officer effective July 1, 2026, with current CEO William “Obi” Greenman becoming Executive Chairman — a clear, pre‑announced succession that typically reduces leadership uncertainty. Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
• Positive Sentiment: Large institutional investors have been increasing positions recently (notably AQR, UBS and Millennium), which can support liquidity and signal professional investor interest.
• Neutral Sentiment: The company disclosed executive compensation adjustments tied to the leadership change; these may be neutral-to-slightly-positive if they align incentives, but they could also increase near‑term dilution depending on grant size and vesting. Compensation Changes
• Negative Sentiment: Multiple insiders sold sizable blocks around $1.66: CEO William Greenman (~447,757 shares), incoming CEO/COO Vivek Jayaraman (~165,200), CFO Kevin Green (~127,544), Richard Benjamin (~101,740) and Chrystal Jensen (~113,008). Collective insider liquidations of this scale can create short‑term downward pressure and raise questions about timing or liquidity needs. CEO SEC Filing Benjamin SEC Filing
• Negative Sentiment: Analyst coverage is mixed-to-negative: recent downgrades (Wall Street Zen cut buy→hold; Zacks to strong sell) leave the consensus at a “Reduce” rating, which can limit upside from new buyers until sentiment improves.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Cibc World Markets Corp purchased a new stake in shares of Cerus in the fourth quarter worth approximately $25,000. CIBC Bancorp USA Inc. purchased a new position in Cerus during the 3rd quarter valued at $31,000. Dynamic Technology Lab Private Ltd bought a new position in Cerus in the 1st quarter valued at $32,000. Aquatic Capital Management LLC bought a new position in Cerus in the 3rd quarter valued at $35,000. Finally, MML Investors Services LLC purchased a new stake in Cerus in the fourth quarter worth $37,000. Institutional investors own 78.37% of the company’s stock.

Wall Street Analyst Weigh In

CERS has been the subject of a number of recent research reports. Wall Street Zen cut Cerus from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. TD Cowen restated a “buy” rating on shares of Cerus in a report on Monday, January 12th. Finally, Zacks Research cut shares of Cerus from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce”.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.